Abstract |
The authors provide a perspective on the rapidly evolving field of prognostic analyses designed to quantify the risk of local recurrence in conservatively treated ductal carcinoma in situ ( DCIS). These include morphologic features variously defined, nomograms, algorithms and multi-gene expression assays-all of which have completed against the perceived conclusions of the randomized trials of irradiation and Tamoxifen for DCIS: "all subsets benefit". At present the majority of newly diagnosed DCIS can be adequately treated with surgery alone. A number will require irradiation to achieve acceptable local control, and a minority will require mastectomy regardless of adjuvant treatments. Differences in the definition of prognostic factors and in the methods used to establish them is a major reason for the lack of consensus in treatment recommendation.
|
Authors | Michael D Lagios, Melvin J Silverstein |
Journal | The breast journal
(Breast J)
2015 Jan-Feb
Vol. 21
Issue 1
Pg. 21-6
ISSN: 1524-4741 [Electronic] United States |
PMID | 25494706
(Publication Type: Historical Article, Journal Article)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Tamoxifen
|
Topics |
- Algorithms
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Breast Neoplasms
(genetics, history, therapy)
- Carcinoma, Intraductal, Noninfiltrating
(genetics, history, therapy)
- Female
- History, 21st Century
- Humans
- Nomograms
- Prognosis
- Randomized Controlled Trials as Topic
- Tamoxifen
(therapeutic use)
- Transcriptome
|